HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Prolymphocytic leukemia.

Abstract
Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T cell, each with its own distinct clinical, laboratory and pathological features. T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy. With the use of the purine analogue pentostatin more than half of patients will have a major response and a minority will have a complete remission, usually lasting months. With the introduction of alemtuzumab, most patients who progressed despite treatment with pentostatin had a major response with a complete remission rate higher than that obtained with pentostatin when used as a first line. Unfortunately, progression still follows shortly. We recommend alemtuzumab as initial therapy and offer stem cell transplant (SCT) to selected young, healthy patients who respond. Although B-cell prolymphocytic leukemia is also a progressive disease, some patients can achieve a prolonged progression-free-survival with fludarabine. Patients presenting with massive splenomegaly may be effectively palliated with splenic irradiation or splenectomy. Rituximab is a promising agent and further investigations are warranted to better define its role in treatment of this disorder.
AuthorsAhmed Absi, Eric Hsi, Matt Kalaycio
JournalCurrent treatment options in oncology (Curr Treat Options Oncol) Vol. 6 Issue 3 Pg. 197-208 (May 2005) ISSN: 1527-2729 [Print] United States
PMID15869731 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Pentostatin
  • alemtuzumab
  • Rituximab
Topics
  • Antibodies, Monoclonal (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm (administration & dosage)
  • Antineoplastic Agents (therapeutic use)
  • Female
  • Humans
  • Leukemia, B-Cell (therapy)
  • Leukemia, Prolymphocytic (therapy)
  • Leukemia, T-Cell (therapy)
  • Male
  • Pentostatin (administration & dosage)
  • Rituximab
  • Stem Cell Transplantation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: